Short Interest in Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Increases By 1,266.3%

by · The Cerbat Gem

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 4,454 shares, an increase of 1,266.3% from the December 15th total of 326 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 825,551 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily trading volume, of 825,551 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Check Out Our Latest Report on Daiichi Sankyo

Daiichi Sankyo Stock Performance

Shares of DSNKY stock opened at $23.06 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.60 and a current ratio of 2.31. The firm has a market capitalization of $43.68 billion and a price-to-earnings ratio of 21.75. Daiichi Sankyo has a one year low of $20.51 and a one year high of $29.68. The company has a 50 day moving average price of $22.36 and a 200 day moving average price of $23.72.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.

Featured Articles